Cargando…

Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa

BACKGROUND: Data on safety and efficacy of second-line tuberculosis drugs in pregnant women and their infants are severely limited due to exclusion from clinical trials and expanded access programs. METHODS: Pregnant women starting treatment for multidrug/rifampicin-resistant (MDR/RR)-tuberculosis a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loveday, Marian, Hughes, Jennifer, Sunkari, Babu, Master, Iqbal, Hlangu, Sindisiwe, Reddy, Tarylee, Chotoo, Sunitha, Green, Nathan, Seddon, James A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028100/ https://www.ncbi.nlm.nih.gov/pubmed/32141495 http://dx.doi.org/10.1093/cid/ciaa189

Ejemplares similares

“Take the treatment and be brave”: Care experiences of pregnant women with rifampicin-resistant tuberculosis
por: Loveday, Marian, et al.
Publicado: (2020)

Healthcare Provider Discrimination toward Pregnant Women with Rifampin-Resistant Tuberculosis
por: Loveday, Marian, et al.
Publicado: (2019)

“A very humiliating illness”: a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa
por: Furin, Jennifer, et al.
Publicado: (2020)

“This is not my body”: Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis
por: Loveday, Marian, et al.
Publicado: (2021)

“I am alive because of her”: factors affecting adherence to combination antiretroviral therapy among people living with HIV in KwaZulu-Natal, South Africa
por: Loveday, Marian, et al.
Publicado: (2022)

‘If I am playing football, I forget that I have this virus’: the challenges and coping strategies of adolescents with perinatally acquired HIV in KwaZulu-Natal, South Africa
por: Loveday, Marian, et al.
Publicado: (2022)

Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa
por: Cox, Helen S., et al.
Publicado: (2015)

MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care
por: Loveday, Marian, et al.
Publicado: (2018)

Individualized Treatment of Multidrug-resistant Tuberculosis Using Whole-Genome Sequencing and Expanded Drug-Susceptibility Testing
por: Dookie, Navisha, et al.
Publicado: (2020)

Tuberculosis Diagnosis and Preventive Monotherapy Among Children and Adolescents Exposed to Rifampicin-Resistant Tuberculosis in the Household
por: Apolisi, Ivy, et al.
Publicado: (2023)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Multidrug-Resistant Bacterial Infections Among Very Low Birthweight Infants With Late-Onset Sepsis in Johannesburg, South Africa
por: Licona, Genesis, et al.
Publicado: (2023)

High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis( )
por: McCallum, Andrew D, et al.
Publicado: (2022)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing
por: Huo, Fengmin, et al.
Publicado: (2020)

Retrospective record review of pregnant women treated for rifampicin-resistant tuberculosis in South Africa
por: van der Walt, Martie, et al.
Publicado: (2020)

Detection of Mycobacterium tuberculosis (MTB) in Fecal Specimens From Adults Diagnosed With Pulmonary Tuberculosis Using the Xpert MTB/Rifampicin Test
por: Kokuto, Hiroyuki, et al.
Publicado: (2015)

Surveillance of Rifampicin Resistance With GeneXpert MTB/RIF in the National Reference Laboratory for Tuberculosis at the Institut Pasteur in Bangui, 2015–2017
por: Farra, Alain, et al.
Publicado: (2019)

rpoB Mutations Causing Discordant Rifampicin Susceptibility in Mycobacterium tuberculosis: Retrospective Analysis of Prevalence, Phenotypic, Genotypic, and Treatment Outcomes
por: Mvelase, Nomonde R, et al.
Publicado: (2019)

Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave
por: Snyman, Jumari, et al.
Publicado: (2021)

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
por: Rockwood, Neesha, et al.
Publicado: (2017)

Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda
por: Ssengooba, Willy, et al.
Publicado: (2021)

Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial( )
por: Paradkar, Mandar S, et al.
Publicado: (2022)

Extensively Drug-Resistant Tuberculosis in Women, KwaZulu-Natal, South Africa
por: O’Donnell, Max R., et al.
Publicado: (2011)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

Should We Use Rifampicin in Periprosthetic Joint Infections Caused by Staphylococci When the Implant Has Been Exchanged? A Multicenter Observational Cohort Study
por: Kramer, Tobias Siegfried, et al.
Publicado: (2023)

Effectiveness of Influenza Vaccination of Pregnant Women for Prevention of Maternal and Early Infant Influenza-Associated Hospitalizations in South Africa: A Prospective Test-Negative Study
por: Nunes, Marta C, et al.
Publicado: (2022)

Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa
por: Salaam-Dreyer, Zubeida, et al.
Publicado: (2021)

Best practices for the care of pregnant people living with TB
por: Maugans, C., et al.
Publicado: (2023)

Using a multimodal strategy to improve patient hand hygiene
por: Loveday, Heather P., et al.
Publicado: (2021)

Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management
por: Prasad, Rajendra, et al.
Publicado: (2018)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial
por: Davis, Angharad G, et al.
Publicado: (2022)

The Impact of Multidrug-Resistant Organisms on Outcomes in Patients With Diabetic Foot Infections
por: Henig, Oryan, et al.
Publicado: (2020)

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis
por: Yun, Hwi-Yeol, et al.
Publicado: (2021)

Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People With HIV
por: Henderson, Heather I, et al.
Publicado: (2022)

The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study
por: Dodd, Peter J, et al.
Publicado: (2022)

High Rates of Potentially Infectious Tuberculosis and Multidrug-Resistant Tuberculosis (MDR-TB) among Hospital Inpatients in KwaZulu Natal, South Africa Indicate Risk of Nosocomial Transmission
por: Bantubani, Nonkqubela, et al.
Publicado: (2014)

Intra-abdominal Infections: The Role of Anaerobes, Enterococci, Fungi, and Multidrug-Resistant Organisms
por: Marcus, Gil, et al.
Publicado: (2016)

Ultraviolet-C Light Evaluation as Adjunct Disinfection to Remove Multidrug-Resistant Organisms
por: Rock, Clare, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9s84gd48nt41s3f34hfiaromoe